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While the safety of endoscopic banding liga-
tion is largely undisputed, there is one major
risk of this technique: esophageal perforation
during insertion of the overtube. Perforation of
the esophagus often occurs as a result of
inability to relax the pharyngeal muscle by the
patient and forceful insertion of the tube by the
endoscopist. The development of multiple band-
ing ligators (Speedband
TM and Six-shooterTM) in
recent years has obviated the use of an overtube
and is truly major advancement. Intubation is
not more difficult with the endoscope loaded
with these multiple band ligators and the
procedure time is significantly shortened [7, 8].
Recently, a detachable mini-loop ligator has
been developed and its use is currently under
investigation.
I believe that endoscopic banding ligation will
continue to gain popularity. Future develop-
ment in this treatment modality should be
directed to the prevention of recurrent varices
formation, the improvement of multiple banding
devices and the study of prophylactic banding
ligation for selected cases with high risk of
variceal bleeding.
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Leak after Whipple Resection" Preventable?
ABSTRACT
Howard, J. M. (1997) Pancreatojejunostomy: Leakage is a
preventable complication of the whipple resection. Journal
of the American College of Surgeons; 184, 454-457.
Background: Leakage of the pancreaticojejunal anastomosis
has been a major complication after pancreaticoduodenect-
omy (Whipple operation), frequently reported in an
incidence of 5 percent to 15 percent. The most widely used
techniques of anastomosis have been variations of end-to-
end pancreaticojejunostomy. Complicating 152 end-to-end
anastomoses, done by me (including 98 for carcinoma of
the pancreas or ampulla), were 5 pancreatic anastomotic
leaks; the fifth patient died of this complication.
Study Design: The death resulting from a pancreatic
anastomotic fistula led me to change my technique to an
end of the pancreas to side of the jejunum, mucosa-to-
mucosa, pancreaticojejunostomy (intubated), a modifica-
tion of the technique described by Cattell and used since134 HPB INTERNATIONAL
1985 by me in 56 consecutive patients. Patients were
monitored for clinical evidence of a pancreatic fistula,
including evaluation of amylase content in serum and, in
most, in peritoneal drainage. Pancreatography through the
exteriorized pancreatic catheter was possible if deemed
advisable.
Results: No pancreatic duct was too small or pancreas too
soft to permit effective anastomosis. No clinical evidence
developed of a pancreatic fistula, "sentinel bleed," or acute
pancreatitis, and no patient was recognized to have a high
amylase content in the peripancreatic peritoneal drainage.
Results of the pancreatogram were negative in three
patients with peripancreatic infections and in one with
severe cholestasis.
Conclusions: Although consensus among surgeons does not
exist as to technique of pancreatic anastomosis, the end-to-
side, mucosa-to-mucosa pancreatico-jejunostomy, intu-
bated, has proved safer in my experience that end-to2end
pancreaticojejunostomy. The experience has led me to
believe that the technique may reduce the incidence of this
fistula and contribute to making pancreaticojejunal leak-
age a preventable complication. J. Am. Coll. Surg., 1997; 184,
454-457.
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PAPER DISCUSSION
The report by John Howard entitled "Pancreato-
jejunostomy: Leakage is a Preventable Compli-
cation of the Whipple Resection" serves as a
personal review of 56 consecutive end-to-side
mucosa-to-mucosa stented pancreaticojejunos-
tomies performed by Dr. Howard since 1985.
Dr. Howard has a superb surgical reputation,
has immense experience with pancreatic sur-
gery, and is perhaps best known as the
individual on whom the character of Trapper
John was based from the long-running hit
television comedy, MASH.
Several points deserve mention regarding this
paper. First, it is beautifully illustrated with four
color plates, which unfortunately are not repro-
duced well by Xeroxing techniques. I would
recommend that anyone interested in reviewing
this technique obtain the original paper as
published in the Journal of the American College
of Surgeons. Second, the author notes that he
performs the jejunal and biliary reconstructions
to a Roux-en-Y segment of jejunum, suggesting
to me that he is using an isolated Roux-en-Y
segment. Third, in order to minimize manipula-
tion of the completed pancreatic anastomosis,
the author performs the choledochojejunostomy
first, subsequently performing the pancreatico-
jejunostomy. Other aspects of this particular
technique include oversewing of the transected
end of the pancreas to augment hemostasis and
minimize leakage of pancreatic juice, the use of a
transanastomotic catheter which is brought out
through the jejunum and the abdominal side
wall, and the anastomosis itself is performed
with interrupted 4-0 polyglycolic acid-type
sutures (Vicryl or Dexon). In the 56 Whipple
procedures performed using this technique, no
patient had a clinically recognized pancreatic
fistula, no patient had evidence of acute pan-
creatitis, and there was only one postoperative
death. These results are impressive and he
should be congratulated. Of course, in the
absence of a comparative group, the importance
of this particular technique in achieving these
outcomes cannot be fully substantiated.
Pancreatic fistula remains a major cause of
morbidity and mortality after pancreaticoduo-
denectomy. The most common techniques for
managing the pancreatic remnant involve a
pancreatic-enteric anastomosis, usually a pan-
creaticojejunostomy or pancreaticogastrostomy.
Many variations of the pancreaticojejunostomy
have been reported including the type of ana-
stomosis (invagination versus duct-to-mucosa)
the use of an isolated Roux-en-Y limb, the use of
pancreatic duct stenting, the site of jejunum
used (end vs. side), as well as the use of fibrin
glue [1-6]. As with many things in surgery,
the lack of agreement regarding the safest
technique of pancreaticojejunostomy suggests
that there may be no one favored technique.
Although limited experiences in dogs have
favored a duct-to-mucosa technique over inva-
gination [7], and stenting over no stenting [3],
prospective, randomized human studies are
unfortunately lacking.HPB INTERNATIONAL 135
Recently pancreaticogastrostomy has gained
favor as a potential means of reducing the
incidence of pancreatic fistula following the
Whipple procedure [8-10]. A prospective, ran-
domized trial from Johns Hopkins enrolled 145
patients and found no differences in the pan-
creatic fistula rates when comparing between
pancreaticojejunostomy and pancreaticogas-
trostomy [11]. Of note, a multivariate logistic
regression analysis performed as part of this
prospective, randomized study revealed that the
two factors most highly associated with pan-
creatic fistula were lower surgical volume, and
either ampullary or duodenal disease in the
resected pathology specimen. Importantly, there
appeared to be a linear relationship between the
number of cases performed during the study
period by each surgeon, and the pancreatic leak
rate, with those surgeons performing the great-
est number of pancreatic-enteric anastomoses
having the lowest leak rate. This underscores the.
importance of the adage "Practice makes per-
fect" and would suggest that an experienced
pancreatic surgeon may be expected to have the
lowest pancreatic fistula rates independent of
the method of pancreatic-enteric reconstruction.
A pharmacologic approach designed to re-
duce the rate of pancreatic fistula involves the
perioperative inhibition of pancreatic exocrine
secretion. To date, four randomized controlled
multicenter trials have evaluated the use of
prophylactic octreotide in patients undergoing
pancreatic resection [12-15]. Each of these trials
was carried out in Europe, used a dose of
octreotide of 100 micrograms every eight hours
for seven to eight days, and analyzed over 200
patients. Each trial reported statistically signifi-
cant decreases in overall morbidity, often not
solely related to pancreatic fistula. Each trial also
reported that the octreotide group had a lower
incidence of pancreatic fistula. In none of the
trials, however, was there a significant decrease
in overall mortality when comparing between
the two groups. Some criticisms have been
generated concering these European multicenter
trials. The trials involved multiple institutions
with varying degrees of surgical expertise in
pancreatic resection. These trials included mul-
tiple types of pancreatic resections, not just
pancreaticoduodenectomies. This is important
because the rate of pancreatic fistula is known to
be lower following distal pancreatectomy, the
Peustow procedure and tumor enucleation, as
compared to pancreaticoduodenectomy. The
trial by Montorsi et al., is the only trial that
specifically noted that the pancreatic fistula rate
following pancreaticoduodenectomy was not
significantly different between the octreotide
and the placebo groups (11% versus 15%),
important information that suggests that octreo-
tide may not lower the pancreatic fistula rate
following the Whipple procedure. Another
aspect of these European multicenter trials that
might be criticized is the high rate of pancreatic
fistula seen in the placebo group, ranging from
19% in the Pederzoli et al., trial to 37% in the
Buchler et al., trial. These rates of pancreatic
fistula are more than double the current pan-
creatic fistula rates seen at many institutions. At
this point it remains unclear how octreotide can
influence the overall morbidity rate and the rate
of pancreatic fistula in patients undergoing
pancreaticoduodenectomy.
There is no doubt that the rate of pancreatic
fistula can be decreased with careful surgical
techniques and with increasing surgical experi-
ence. At this point it is unclear whether
pancreatic ductal stenting, a specific type
of pancreatic-enteric anastomosis or the use of
octreotide actually will decrease the rates of
pancreatic fistula. I must admit that I currently
favor an end-to-side pancreaticojejunostomy,
performed in two layers, attempting to incorpo-
rate the pancreatic duct in the inner layer of the
anastomosis. I do not use pancreatic ductal
stents, I do not spray the anastomosis with
fibrin glue, and I do place small bore closed
suction drains close to (but not on) the anasto-136 HPB INTERNATIONAL
mosis. In our experience, roughly 10% of
patients will have low volume amylase-rich
fluid draining via the drains. Over 85% of these
low volume pancreatic fistulas will heal with
conservative management. While pancreatic
fistula has not disappeared as a postoperative
complication, it is certainly no longer the
dreaded and feared complication that it was
several decades ago. As additional experience
and data are gathered, perhaps one particular
technique of pancreatic reanastomosis will as-
sume priority.
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Budd-Chiari Syndrome" Shunt or Transplant?
ABSTRACT
Hemming, A. W., Langer, B., Greig, P., Taylor, B. R.
Adams, R. and Heathcote, J. (1996) Treatment of Budd-
Chiari syndrome with portosystemic shunt or liver
transplantation. The American Journal of Surgery; 171:
176-181.
Background: Budd-Chiari syndrome is an uncommon
disorder caused by obstruction to hepatic venous outflow,
causing varying degrees of hepatic injury depending on the
extent, severity, and acuity of the obstruction.
Patients and Methods: We reviewed the indications for
operative intervention and the results of treating 32
patients with Budd-Chiari syndrome seen at Toronto
Hospital between 1968 and 1995.
Results: Twenty-one patients underwent porto-systemic
shunt (PSS) and 7 patients underwent liver transplantation
(LT) as their initial operative management. Three patients
who initially had PSS subsequently required LT. Patients
with cirrhosis found on biopsy and preservation of
hepatocellular function were treated with PSS and showed